Abstract
Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 847-852 |
| Number of pages | 6 |
| Journal | Immunotherapy |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| State | Published - Jul 2016 |
Keywords
- Biphenotypic acute leukemia
- CD19
- blinatumomab
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
Fingerprint
Dive into the research topics of 'Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS